A spin-out from Harvard, Nabla Bio is structured around development of novel proteins intended for medical and industrial applications. Applying AI technology to antibody design, the company's supernatural proteins are extrapolated from insights learned from billions of natural ones and are enhanced through diverse protein variants through numerous experiments, enabling clients to carry out implementations involving complex measurements of protein function. Indicating that the next generation of antibodies will be designed rather than discovered, and these designs will be aided by artificial intelligence.
